经导管肝动脉化疗栓塞术联合三维适形放疗治疗巨大原发性肝癌疗效分析  

Efficacy of transcatheter arterial chemoembolization combined with three-dimensional conformal radiation therapy in the treatment of patients with massive primary liver cancer

作　　者：周蔼斌 周俊平[1] 芦东徽[1] 张立洁[1] 徐滨[1] 张厚安[2] 管连敏 Zhou Aibin Zhou Junping Lu Donghui et al(Diagnosis and Treatment Center for Cancer Research,105th Hospital of PLA ,Hefei 230031 ,A nhui Province, China)

机构地区：[1]解放军第105医院肿瘤中心,合肥市230031 [2]解放军第105医院介入科,合肥市230031 [3]蚌埠医学院普外科

出　　处：《实用肝脏病杂志》2017年第2期195-198,共4页Journal of Practical Hepatology

摘　　要：目的探讨经导管肝动脉化疗栓塞术(TACE)联合三维适形放疗(3D-CRT)治疗巨大原发性肝癌患者的疗效。方法回顾性分析2009年1月~2015年1月我院诊治的147例无法手术切除的巨大(直径≥10cm)原发性肝癌。根据治疗方案不同,分为TACE联合3D-CRT治疗63例和TACE治疗84例,比较分析两组患者治疗效果,并记录治疗期间不良反应发生情况。结果 TACE联合3D-CRT组有效率为65.1%,显著高于TACE组的40.5%(P<0.05);TACE联合3D-CRT组和单纯TACE组6 m、1 a、2 a生存率分别为84.1%、55.6%、27.0%和59.5%、38.1%、19.1%,其中两组6 m和1 a年生存率比较有统计学差异(P<0.05);两组不良反应发生率比较无显著差异。结论 TACE联合3D-CRT治疗无法手术切除的巨大原发性肝癌具有良好的临床疗效。Objective To explore the clinical efficacy of transcatheter arterial chemoembolization （TACE） combined with three-dimensional conformal radiation therapy （3D-CRT） in the treatment of patients with massive primary liver cancer （PLC）. Methods From January 2009 to January 2015,147 nnresectable massive PLC（tnmor size≥10 cm） patients in our hospital were divided into TACE plus 3D-CRT group （n=63） and TACE group（n= 84） according to different treatment methods. Curative effects in the two groups were compared,and the adverse reaction during treatment period were recorded. Results The effective rate was 65.1% in the TACE plus 3D- CRT group,significantly higher than 40.5% in the TACE group （P〈0.05）;The 6-month,l-year and 2-year survival rates were 84.1%,55.6% and 27.0%,respectively,in the TACE plus 3D-CRT group,and 59.5% （P〈 0.05）,38.1% （P〈0.05） and 19.1% （P〉0.05）,respectively, in the TACE group;The adverse reactions in the two groups were not significantly different. Conclusion TACE combined with 3D-CRT therapy for unresectable massive PLC has good clinical efficacy.

关 键 词：原发性肝癌 肝动脉化疗栓塞 三维适形放疗 治疗 

分 类 号：R735.7[医药卫生—肿瘤]